GEP20074024B - Polyalkylene glycol comprising a radical for conjugation of biologically active compound - Google Patents

Polyalkylene glycol comprising a radical for conjugation of biologically active compound

Info

Publication number
GEP20074024B
GEP20074024B GEAP20038365A GEAP2003008365A GEP20074024B GE P20074024 B GEP20074024 B GE P20074024B GE AP20038365 A GEAP20038365 A GE AP20038365A GE AP2003008365 A GEAP2003008365 A GE AP2003008365A GE P20074024 B GEP20074024 B GE P20074024B
Authority
GE
Georgia
Prior art keywords
conjugation
radical
active compound
biologically active
polyalkylene glycol
Prior art date
Application number
GEAP20038365A
Other languages
English (en)
Inventor
Darren P Baker
Russell C Petter
Edward Y Lin
Donna M Hess
Ling Ling Chen
R Blake Pepinsky
Kochung Lin
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Publication of GEP20074024B publication Critical patent/GEP20074024B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/34—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from hydroxy compounds or their metallic derivatives
    • C08G65/48—Polymers modified by chemical after-treatment
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L71/00—Compositions of polyethers obtained by reactions forming an ether link in the main chain; Compositions of derivatives of such polymers
    • C08L71/02—Polyalkylene oxides
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2203/00—Applications
    • C08L2203/02—Applications for biomedical use

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Polymers & Plastics (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Polyethers (AREA)
GEAP20038365A 2002-01-18 2003-01-17 Polyalkylene glycol comprising a radical for conjugation of biologically active compound GEP20074024B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34991702P 2002-01-18 2002-01-18

Publications (1)

Publication Number Publication Date
GEP20074024B true GEP20074024B (en) 2007-01-10

Family

ID=27613339

Family Applications (2)

Application Number Title Priority Date Filing Date
GEAP20038365A GEP20074024B (en) 2002-01-18 2003-01-17 Polyalkylene glycol comprising a radical for conjugation of biologically active compound
GEAP8365A GEP20064024B (en) 2002-01-18 2003-01-17 Polyalkylene glycol comprising a radical for conjugation of biologically active compound

Family Applications After (1)

Application Number Title Priority Date Filing Date
GEAP8365A GEP20064024B (en) 2002-01-18 2003-01-17 Polyalkylene glycol comprising a radical for conjugation of biologically active compound

Country Status (35)

Country Link
US (2) US8017733B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (3) EP1476181B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (5) JP2005526151A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR100964411B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (2) CN101700401B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2003210564B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE (1) BE2016C040I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BG (1) BG66525B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BRPI0306993B8 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (4) CA2952488C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CY (2) CY2016027I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CZ (1) CZ2004877A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (2) DK1476181T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EA (2) EA009783B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EE (1) EE05509B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (2) ES2774801T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (1) FR16C0034I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GE (2) GEP20074024B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (4) HUE028163T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL163006A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IS (1) IS2989B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LU (1) LU93162I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ME (2) MEP35608A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MXPA04006855A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NL (1) NL300826I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (3) NO339857B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ534708A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (2) PL213322B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT3025726T (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RS (1) RS55578B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SI (2) SI1476181T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SK (1) SK3102004A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UA (1) UA82184C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2003061577A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA200406555B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL213322B1 (pl) * 2002-01-18 2013-02-28 Biogen Idec Inc Kompozycja farmaceutyczna zawierajaca polimer glikolu polialkilenowego skoniugowany z biologicznie aktywnym zwiazkiem lub jego prekursorem oraz jej zastosowania
US20150246097A9 (en) * 2002-01-18 2015-09-03 Biogen Idec Ma Inc. Polyalkylene Polymer Compounds and Uses Thereof
UA80838C2 (en) 2002-09-09 2007-11-12 Water-soluble polymer alkanals
US8129330B2 (en) 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
AU2003303636B2 (en) * 2002-12-26 2010-08-05 Mountain View Pharmaceuticals, Inc. Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
TWI406672B (zh) 2002-12-26 2013-09-01 Mountain View Pharmaceuticals 生物效力增進的β干擾素聚合物共軛體
US7432331B2 (en) 2002-12-31 2008-10-07 Nektar Therapeutics Al, Corporation Hydrolytically stable maleimide-terminated polymers
CN100343304C (zh) 2002-12-31 2007-10-17 尼克塔治疗亚拉巴马公司 水解稳定的马来酰亚胺封端的聚合物
TWI367103B (en) 2003-06-26 2012-07-01 Psivida Inc Bioerodible sustained release drug delivery systems
WO2005002625A2 (en) 2003-06-26 2005-01-13 Control Delivery Systems, Inc. In-situ gelling drug delivery system
WO2005118537A2 (en) * 2004-05-31 2005-12-15 Ranbaxy Laboratories Limited Arylpiperazine derivatives as adrenergic receptor antagonists
AU2005318984B2 (en) 2004-12-21 2011-12-01 Nektar Therapeutics Stabilized polymeric thiol reagents
US20070004635A1 (en) * 2005-06-02 2007-01-04 Schering Corporation Method of treating interferon non-responders using HCV protease inhibitor
KR20080031053A (ko) * 2005-07-08 2008-04-07 엘란 파마슈티칼스, 인크. 치료, 농업 및 식품 첨가제 화합물의 중합체 컨쥬게이트의제조 방법
EA015528B1 (ru) * 2006-05-22 2011-08-30 Элан Фармасьютикалз, Инк. Получение полимерных конъюгатов соединений, применяемых в терапии, сельском хозяйстве и в качестве пищевых добавок
US20100222546A1 (en) * 2006-11-28 2010-09-02 David Crich Methods for the preparation of functionalized peptides, proteins and carbohydrates and their conjugates
CA2693645A1 (en) * 2007-07-11 2009-01-15 Enzon Pharmaceuticals, Inc. Polymeric drug delivery systems containing an aromatic allylic acid
JP2010533202A (ja) * 2007-07-11 2010-10-21 エンゾン ファーマシューティカルズ，インコーポレーテッド 多置換芳香族部分を含むポリマー性薬剤送達システム
CL2008002399A1 (es) * 2007-08-16 2009-01-02 Pharmaessentia Corp Conjugado sustancialmente puro que posee una porcion polimerica, una porcion proteica (interferon alfa 2b) y un ligante alifatico de 1 a 10 atomos de carbono, util en el tratamiento de las hepatitis b o c.
CN103536906A (zh) * 2008-06-05 2014-01-29 津莫吉尼蒂克斯公司 利用聚乙二醇化的iii 型干扰素治疗丙型肝炎
UA104146C2 (ru) * 2008-07-31 2014-01-10 Фармаиссеншиа Корп. ПОЛИМЕРНЫЕ КОНЪЮГАТЫ ФРАГМЕНТОВ ИНТЕРФЕРОНА-β, ЭРИТРОПОЭТИНА И ГОРМОНА РОСТА
GB0823309D0 (en) * 2008-12-19 2009-01-28 Univ Bath Functionalising reagents and their uses
EP2439736A1 (en) 2009-06-02 2012-04-11 Panasonic Corporation Down-mixing device, encoder, and method therefor
UA109646C2 (uk) * 2009-12-10 2015-09-25 Терапевтичне застосування кон'югатів білка з полімером
US20130225789A1 (en) * 2012-02-29 2013-08-29 Yi Sun Polyethylene Glycol Having Hetero Multiple Functional Groups
US8993614B2 (en) 2012-03-15 2015-03-31 F. Hoffmann-La Roche Ag Substituted pyrrolidine-2-carboxamides
KR101475630B1 (ko) * 2013-05-31 2014-12-22 동국대학교 산학협력단 포도근 추출물 또는 이의 분획물을 유효성분으로 포함하는 c형 간염의 예방 또는 치료용 조성물
WO2016013911A1 (ko) * 2014-07-24 2016-01-28 에이비온 주식회사 페길화된 인터페론 -베타 변이체
ES2824028T3 (es) * 2014-08-19 2021-05-11 Biogen Ma Inc Método de PEGilación
GB201419108D0 (en) 2014-10-27 2014-12-10 Glythera Ltd Materials and methods relating to linkers for use in antibody drug conjugates
CN107530403A (zh) 2014-11-06 2018-01-02 药华医药股份有限公司 用于长效型干扰素的剂量方案
ES2831079T3 (es) * 2017-06-28 2021-06-07 Construction Research & Technology Gmbh Dispersante para partículas inorgánicas
US11472894B2 (en) 2018-07-23 2022-10-18 Carnegie Mellon University Enzyme-assisted ATRP procedures
US12053529B2 (en) 2018-08-01 2024-08-06 Carnegie Mellon University Amino-reactive positively charged ATRP initiators that maintain their positive charge during synthesis of biomacro-initiators
CN109232898A (zh) * 2018-08-02 2019-01-18 张玲 一种具有抗凝血功能的聚酰亚胺新材料的制备方法
CN111534458B (zh) * 2020-04-13 2022-01-14 浙江工业大学 无色杆菌tbc-1及其在降解1,3,6,8-四溴咔唑中的应用
CN113716982B (zh) * 2021-08-24 2022-05-06 重庆云瑞肥业有限公司 一种食品垃圾回收用发酵制肥装置

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4002531A (en) * 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
EP0082481B2 (en) 1981-12-23 1990-09-12 Schering Corporation Stabilised alpha-interferon formulations and their preparation
WO1985003934A1 (en) * 1984-03-06 1985-09-12 Takeda Chemical Industries, Ltd. Chemically modified protein and process for its preparation
GB8334102D0 (en) * 1983-12-21 1984-02-01 Searle & Co Interferons with cysteine pattern
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
DE3676670D1 (de) 1985-06-26 1991-02-07 Cetus Corp Solubilisierung von proteinen fuer pharmazeutische zusammensetzungen mittels polymerkonjugierung.
JP2514950B2 (ja) 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー 化学修飾蛋白質，その製造法および中間体
US4894226A (en) * 1986-11-14 1990-01-16 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polyproline conjugation
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5135919A (en) 1988-01-19 1992-08-04 Children's Medical Center Corporation Method and a pharmaceutical composition for the inhibition of angiogenesis
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5286637A (en) * 1989-08-07 1994-02-15 Debiopharm, S.A. Biologically active drug polymer derivatives and method for preparing same
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5281698A (en) 1991-07-23 1994-01-25 Cetus Oncology Corporation Preparation of an activated polymer ester for protein conjugation
AU3423293A (en) * 1991-12-19 1993-07-19 Baylor College Of Medicine Pva or peg conjugates of peptides for epitope-specific immunosuppression
ZA933926B (en) * 1992-06-17 1994-01-03 Amgen Inc Polyoxymethylene-oxyethylene copolymers in conjuction with blomolecules
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US5262564A (en) 1992-10-30 1993-11-16 Octamer, Inc. Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
US5298410A (en) * 1993-02-25 1994-03-29 Sterling Winthrop Inc. Lyophilized formulation of polyethylene oxide modified proteins with increased shelf-life
US5359030A (en) 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5681811A (en) 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
US5874075A (en) * 1993-10-06 1999-02-23 Amgen Inc. Stable protein: phospholipid compositions and methods
US5951974A (en) 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
DE69430251T2 (de) 1993-11-10 2002-11-07 Enzon, Inc. Verbesserte interferon-polymerkonjugate
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5639725A (en) 1994-04-26 1997-06-17 Children's Hospital Medical Center Corp. Angiostatin protein
US5730990A (en) 1994-06-24 1998-03-24 Enzon, Inc. Non-antigenic amine derived polymers and polymer conjugates
US5650234A (en) 1994-09-09 1997-07-22 Surface Engineering Technologies, Division Of Innerdyne, Inc. Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5738846A (en) 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
MX9704137A (es) * 1994-12-07 1997-09-30 Novo Nordisk As Polipeptidos de alergenicidad reducida.
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
SE9503380D0 (sv) * 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
AU730969B2 (en) * 1995-10-19 2001-03-22 University Of Washington Discrete-length polyethylene glycols
US5702717A (en) * 1995-10-25 1997-12-30 Macromed, Inc. Thermosensitive biodegradable polymers based on poly(ether-ester)block copolymers
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US5747639A (en) * 1996-03-06 1998-05-05 Amgen Boulder Inc. Use of hydrophobic interaction chromatography to purify polyethylene glycols
WO1998032466A1 (en) 1997-01-29 1998-07-30 Polymasc Pharmaceuticals Plc Pegylation process
CN1268980A (zh) 1997-03-05 2000-10-04 华盛顿州大学 用于鉴定选择性抑制丙型肝炎病毒复制的试剂的新筛选方法
US5990237A (en) * 1997-05-21 1999-11-23 Shearwater Polymers, Inc. Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines
US6448369B1 (en) * 1997-11-06 2002-09-10 Shearwater Corporation Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation
US7642323B2 (en) * 1997-11-06 2010-01-05 Nektar Therapeutics Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation
US6180095B1 (en) * 1997-12-17 2001-01-30 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
AU1825299A (en) * 1997-12-17 1999-07-05 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
US5981709A (en) 1997-12-19 1999-11-09 Enzon, Inc. α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same
US5985263A (en) 1997-12-19 1999-11-16 Enzon, Inc. Substantially pure histidine-linked protein polymer conjugates
US5965119A (en) * 1997-12-30 1999-10-12 Enzon, Inc. Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents
EP1061954B1 (en) * 1998-03-12 2004-06-09 Nektar Therapeutics Al, Corporation Poly(ethylene glycol) derivatives with proximal reactive groups
AU762621B2 (en) * 1998-04-28 2003-07-03 Merck Serono Sa Polyol-IFN-beta conjugates
US6703381B1 (en) 1998-08-14 2004-03-09 Nobex Corporation Methods for delivery therapeutic compounds across the blood-brain barrier
AU762616B2 (en) * 1998-10-16 2003-07-03 Biogen Ma Inc. Polymer conjugates of interferon beta-1a and uses
WO2001000246A2 (en) * 1999-06-11 2001-01-04 Shearwater Corporation Hydrogels derived from chitosan and poly(ethylene glycol)
US7144574B2 (en) * 1999-08-27 2006-12-05 Maxygen Aps Interferon β variants and conjugates
US6531122B1 (en) * 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates
SK2942002A3 (en) 1999-08-27 2002-08-06 Maxygen Aps A conjugate exhibiting interferon beta, a nucleotide sequence, an expressing vector, a host cell containing such a nucleotide sequence, method for the preparation thereof, pharmaceutical composition containing the same and its use
US6495659B2 (en) * 1999-12-22 2002-12-17 Shearwater Corporation Sterically hindered poly(ethylene glycol) alkanoic acids and derivatives thereof
US6413507B1 (en) * 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
AU2001296962A1 (en) * 2000-09-29 2002-04-08 Schering Corporation Pegylated interleukin-10
US7053150B2 (en) * 2000-12-18 2006-05-30 Nektar Therapeutics Al, Corporation Segmented polymers and their conjugates
TW593427B (en) * 2000-12-18 2004-06-21 Nektar Therapeutics Al Corp Synthesis of high molecular weight non-peptidic polymer derivatives
KR100872807B1 (ko) * 2001-02-01 2008-12-09 바이오겐 아이덱 엠에이 인코포레이티드 누블라스틴의 중합체 컨쥬게이트 및 이의 사용 방법
DE60232434D1 (de) 2001-02-27 2009-07-09 Maxygen Aps Neue interferon-beta-ähnliche moleküle
US7009033B2 (en) * 2001-07-02 2006-03-07 Polymer Source Inc. Heterofunctional polyethylene glycol and polyethylene oxide, process for their manufacture
DK2939696T3 (en) * 2001-10-18 2016-05-23 Nektar Therapeutics Polymer Conjugates of Opioid Antagonists
IL162031A0 (en) * 2001-11-20 2005-11-20 Pharmacia Corp Chemically-modified human growth hormone conjugates
US6956135B2 (en) * 2001-12-11 2005-10-18 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
KR100488351B1 (ko) * 2001-12-11 2005-05-11 선바이오(주) 신규한 폴리에틸렌글리콜-프로피온알데히드 유도체
EP1507755A4 (en) * 2001-12-11 2006-05-17 Sun Bio Inc NOVEL MONOFUNCTIONAL POLYETHYLENE GLYCOL ALDEHYDES
US7041855B2 (en) * 2001-12-11 2006-05-09 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
US6916962B2 (en) 2001-12-11 2005-07-12 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
PL213322B1 (pl) 2002-01-18 2013-02-28 Biogen Idec Inc Kompozycja farmaceutyczna zawierajaca polimer glikolu polialkilenowego skoniugowany z biologicznie aktywnym zwiazkiem lub jego prekursorem oraz jej zastosowania
UA80838C2 (en) * 2002-09-09 2007-11-12 Water-soluble polymer alkanals
TWI406672B (zh) * 2002-12-26 2013-09-01 Mountain View Pharmaceuticals 生物效力增進的β干擾素聚合物共軛體
US20110165122A1 (en) * 2009-11-10 2011-07-07 The Regents Of The University Of California Method for targeted and sustained antiviral therapy

Also Published As

Publication number Publication date
BR0306993A (pt) 2005-09-06
NO20151082A1 (no) 2015-08-26
HU230473B1 (hu) 2016-07-28
IS7353A (is) 2004-07-15
LU93162I2 (fr) 2016-10-03
HUE047557T2 (hu) 2020-04-28
HK1224185A1 (en) 2017-08-18
EP1476181A2 (en) 2004-11-17
BRPI0306993B1 (pt) 2020-03-10
US20120014916A1 (en) 2012-01-19
CN101700401A (zh) 2010-05-05
AU2003210564B2 (en) 2008-10-23
WO2003061577A2 (en) 2003-07-31
DK3025726T3 (da) 2019-12-09
FR16C0034I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2016-09-23
KR100964411B1 (ko) 2010-06-15
US8017733B2 (en) 2011-09-13
MXPA04006855A (es) 2005-04-19
SK3102004A3 (sk) 2005-01-03
CA2952488C (en) 2019-05-07
ES2566797T3 (es) 2016-04-15
EP3025726B1 (en) 2019-11-20
RS63504A (en) 2007-02-05
WO2003061577A3 (en) 2003-10-02
EE05509B1 (et) 2012-02-15
US8524660B2 (en) 2013-09-03
CY2016027I1 (el) 2017-06-28
NL300826I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2017-03-16
HUE028163T2 (en) 2016-11-28
EP3025726A1 (en) 2016-06-01
JP6030717B2 (ja) 2016-11-24
JP2012255156A (ja) 2012-12-27
NO20043422L (no) 2004-10-11
SI3025726T1 (sl) 2020-03-31
ME00239B (me) 2011-05-10
DK1476181T3 (en) 2016-05-23
RS55578B1 (sr) 2017-06-30
SI1476181T1 (sl) 2016-10-28
HUP0500457A2 (hu) 2005-08-29
IS2989B (is) 2017-11-15
CA2753899A1 (en) 2003-07-31
BRPI0306993B8 (pt) 2021-05-25
HUS1600035I1 (hu) 2016-10-28
EA200701386A1 (ru) 2007-10-26
IL163006A (en) 2011-01-31
GEP20064024B (en) 2007-01-10
HK1143553A1 (en) 2011-01-07
HK1072721A1 (zh) 2005-09-09
ES2774801T3 (es) 2020-07-22
JP2009235409A (ja) 2009-10-15
EA011829B1 (ru) 2009-06-30
UA82184C2 (uk) 2008-03-25
CN1630530A (zh) 2005-06-22
NZ534708A (en) 2007-05-31
WO2003061577A8 (en) 2008-11-20
MEP35608A (hr) 2011-02-10
PT3025726T (pt) 2020-01-09
ZA200406555B (en) 2005-11-30
HUP0500457A3 (en) 2012-09-28
EP3669887A1 (en) 2020-06-24
PL213322B1 (pl) 2013-02-28
FR16C0034I2 (fr) 2019-10-04
US20050107277A1 (en) 2005-05-19
CZ2004877A3 (cs) 2004-12-15
CY1122841T1 (el) 2021-10-29
EA009783B1 (ru) 2008-04-28
EP1476181A4 (en) 2008-11-19
CY2016027I2 (el) 2017-06-28
NO339857B1 (no) 2017-02-06
KR20040081463A (ko) 2004-09-21
CA2473526A1 (en) 2003-07-31
CA2840490A1 (en) 2003-07-31
EE200400105A (et) 2004-12-15
NO344612B1 (no) 2020-02-10
CA2840490C (en) 2017-02-28
BG66525B1 (bg) 2016-04-28
JP2005526151A (ja) 2005-09-02
CA2952488A1 (en) 2003-07-31
EP1476181B1 (en) 2016-03-23
PL372728A1 (en) 2005-08-08
CA2753899C (en) 2014-03-25
EA200400962A1 (ru) 2005-06-30
CN101700401B (zh) 2013-08-14
NO2017013I1 (no) 2017-04-10
BE2016C040I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2022-05-17
JP2016014022A (ja) 2016-01-28
PL397261A1 (pl) 2012-03-26
NO2017013I2 (no) 2018-08-20
BG108839A (bg) 2005-04-30
JP5275125B2 (ja) 2013-08-28
CA2473526C (en) 2013-10-22
JP2013136756A (ja) 2013-07-11

Similar Documents

Publication Publication Date Title
GEP20074024B (en) Polyalkylene glycol comprising a radical for conjugation of biologically active compound
SE0300010D0 (sv) Novel Compounds
IS6658A (is) Ný efnasambönd
AP1818A (en) Urea-compounds active as vanilloid receptor antagonists for the treatment of pain
GEP20063938B (en) Hepatitis c virus inhibitors
GEP20084329B (en) 5,7-diaminopyrazolo [4,3-d] pyrimidines useful in the treatment of hypertension
IL163552A (en) Conjugates of biologically active compounds, uses thereof and pharmaceutical compositions comprising the same
TW200738658A (en) Novel compounds
NZ526088A (en) Urea substituted imidazoquinoline ethers
DK1157037T3 (da) GCSF-konjugater
SE0102315D0 (sv) Compounds
GEP20053473B (en) High Potency Dihydroergotamine Compositions
GEP20074099B (en) 3-β-D-RIBOFURANO-SYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF
MY128924A (en) Novel compounds
GB0011203D0 (en) Chemical compounds
DE69940635D1 (de) Copolymer-zusammensetzungen zur oralen verabreichung
GEP20094834B (en) Macrolides, pharmaceutical compositions containing them and their use for treatment of bacterial infections
DE602004011966D1 (en) Heterocyclylverbindungen
SE0302139D0 (sv) Novel compounds
SE9902765D0 (sv) Novel compounds
SE0302116D0 (sv) Novel compounds
TW200604197A (en) New compounds
EP0992509A3 (en) Novel macrolide derivatives
EP1379508A4 (en) N- (ARYL) -2-ARYLETHESULFONAMIDES AND THEIR THERAPEUTIC APPLICATIONS
IL157653A0 (en) Novel amides, preparation and therapeutic use as modulators of ccr-receptor activity